Abstracts tagged "interleukins (IL)"

Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting
COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic
Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…
Abstract Number: 1168 • 2013 ACR/ARHP Annual Meeting
Innate Immune Cell Production Of Interleukin-12 Drives CpG-Induced Macrophage Activation Syndrome
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatrics/Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Hemophagocytic syndromes are caused by an uncontrolled systemic inflammatory response resulting in cytopenias, multisystem organ failure, and rapid death, often despite aggressive therapy. Macrophage…
Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting
The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF
Christine Huppertz, Marija Curcic Djuric, Robert Hennze and Frank Kolbinger, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland
Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…
Abstract Number: 939 • 2013 ACR/ARHP Annual Meeting
Reduction Of Circulating Blood Neutrophils In Mice By Anti-IL-6R Alpha Monoclonal Antibody is Not Due To Apoptosis Or Blockade Of Neutrophil Differentiation
Ludmila Kelly, Vilma Decman and Dimitris Skokos, Research, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Blockade of IL-6/IL-6Rα signaling is associated with a reduction of circulating neutrophils in the blood of patients treated with anti-IL-6Rα mAb but the mechanism…
Abstract Number: 931 • 2013 ACR/ARHP Annual Meeting
Effect Of Neutralizing IL-17A and IL-17F Antibodies On Host Resistance To Acute Mycobacterium Tuberculosis Infection In Mice In Comparison With Neutralizing TNF-α Treatment
Michael Kammüller¹, Franco Di Padova², Christian Antoni³, Salah-Dine Chibout⁴, Timothy Wright⁵, Marie-Laure Bourigault⁶, Noria Segueni⁶, Stephanie Rose⁶, Bernhard Ryffel⁶ and Valerie Quesniaux⁶, ¹PCS - Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland, ²Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶UMR7355 CNRS and University of Orleans, Orleans, France
Background/Purpose: Antibodies targeting IL-17A or IL-17RA are in clinical trials for the treatment of several autoimmune diseases. However, these therapies, by blocking critical mediators of…
Abstract Number: 940 • 2013 ACR/ARHP Annual Meeting
Novel Function Of Soluble Interleukin-6 Receptor As An Antagonist Of Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume¹, Keiko Esaki², Keiko Yoshimoto³, Hideto Kameda³, Tsutomu Takeuchi³ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The immunological roles of interleukin 27 (IL-27) have been reported in various rheumatic diseases, such as rheumatoid arthritis (RA), lupus, systemic sclerosis and psoriasis.…
Abstract Number: 943 • 2013 ACR/ARHP Annual Meeting
Synergism Between Granulocyte-Macrophage Colony Stimulating Factor and Interleukin-17 Causes Joint Damage Via The Production Of Interleukin-23, Receptor Activator Of NF-κB Ligand and S100A8
Annemarie E.M. Van Nieuwenhuijze¹, Fons A.J. Van de Loo², Birgitte Walgreen³, Miranda B. Bennink⁴, Monique M. Helsen³, Liduine Van den Bersselaar¹, Ian P. Wicks^5,6, Wim B. Van den Berg⁷ and Marije I. Koenders⁷, ¹Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia, ⁶Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ⁷Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…
Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting
Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Sebastian Kraus¹, Matthias Englbrecht¹, Juergen Rech², Roland Kocijan¹, Georg A. Schett¹ and Stephanie Finzel¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…
Abstract Number: 948 • 2013 ACR/ARHP Annual Meeting
Dual Neutralization Of TNF and IL-17 Provides Greater Efficacy In Collagen Induced Arthritis Through Regulation Of a Gene Transcription Program That Includes CXCL1 and CXCL5
Carolyn Cuff¹, Chung-Ming Hsieh², Suzanne Mathieu³, Anwar Murtaza⁴, Margaret Hugunin³, Shaughn Bryant³, Robert O'brien³, Lisa Olson⁵ and Jeffrey Voss³, ¹Immunology, AbbVie, Inc, Worcester, MA, ²Biologics, AbbVie Pharmaceuticals, Worcester, MA, ³Immunology, AbbVie Pharmaceuticals, Worcester, MA, ⁴Broad Institute, Cambridge, MA, ⁵AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Dual neutralization of TNF and IL-17 is hypothesized to provide greater efficacy in rheumatoid arthritis (RA) and inflammatory diseases compared to either monotherapy as…
Abstract Number: 2695 • 2013 ACR/ARHP Annual Meeting
Host Genetic Background Disrupts The Relationship Between Microbiota and Gut Mucosal Tolerance Leading To Spondyloarthritis and Ileitis After a Dectin-1 Trigger
Linda Rehaume¹, Stanislas Mondot², Daniel Aguirre de Cárcer², Jared Velasco¹, Helen Benham¹, Sumaira Hasnain³, Jaclyn Bowman¹, Merja Ruutu¹, Philip Hansbro⁴, Michael McGuckin³, Mark Morrison² and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²CSIRO Livestock Industries, Brisbane, Australia, ³Mater Medical Research Institute, Brisbane, Australia, ⁴Center for Asthma and Respiratory Disease and Hunter Medical Research Institute, Newcastle, Australia
Background/Purpose: Chronic inflammatory diseases known as spondyloarthropathies (SpA) including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and arthritis associated with inflammatory bowel disease, collectively affect 3%…
Abstract Number: 918 • 2013 ACR/ARHP Annual Meeting
Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis
Koichi Yanaba¹ and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Psoriasis is a cutaneous disorder characterized by widespread erythematous plaques with adherent scales. Recent studies have revealed that both T helper (Th) 17 and…
Abstract Number: 2500 • 2013 ACR/ARHP Annual Meeting
Mast Cells Are a Major Source Of IL-17 In Synovium and Extra-Articular Tissues In Spondyloarthritis Related Diseases
T. Noordenbos¹, I. Gofita¹, M. Alsina², E.W.M. Vogels³, A. A. te Velde³, J. D. Cañete⁴, Dominique L. Baeten⁵ and N. Yeremenko¹, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain, ³Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre/University of Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17 plays a key role in the pathogenesis of spondyloarthritis (SpA) as demonstrated by a recent proof-of-concept trial with the anti-IL17A mAb secukinumab. The…
Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting
Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages
Christian Beyer¹, Jürgen Beer¹, Katrin Palumbo-Zerr¹, Pawel Zerr¹, Alfiya Distler¹, Clara Dees¹, Louis E. Munoz¹, Gerhard Krönke¹, Oliver Distler², Steve Anderson³, Georg A. Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Lexicon Pharmaceuticals Inc., The Woodlands, TX, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…
Abstract Number: 2503 • 2013 ACR/ARHP Annual Meeting
IL-17+ CD8+ T Cells Are Enriched In The Joints Of Patients With Psoriatic Arthritis and Correlate With Markers Of Disease Activity and Joint Damage Progression
Bina Menon^1,2, Nicola J. Gullick³, Hayley G. Evans⁴, Gina J. Walter⁴, Megha Rajasekhar⁴, Toby Garrood², Leonie S. Taams⁴ and Bruce W. Kirkham², ¹Centre for Cellular and Molecular Biology of Inflammation, King's College London, London, United Kingdom, ²Rheumatology, Guy's and St. Thomas' Foundation Hospital NHS Trust, London, United Kingdom, ³Rheumatology, King's College Hospital Foundation NHS Trust, London, United Kingdom, ⁴Centre for Molecular and Cellular Biology of Inflammation, King's College London, London, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) have clear differences in clinical, radiological and genetic features, suggesting that the immunopathology of the conditions may…
Abstract Number: 595 • 2013 ACR/ARHP Annual Meeting
Anemic Hypoxia Is Associated With Pulmonary Arterial Hypertension In Patients With Systemic Lupus Erythematosus
Ki-Jo Kim¹, In-Woon Baek², Chong-Hyeun Yoon³, Jin-Jung Choi⁴, Wan-Uk Kim² and Chul-Soo Cho⁵, ¹Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, ²Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁴Internal Medicine, CHA University Hospital, Seongnam, South Korea, ⁵Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of systemic lupus erythematosus (SLE), but its pathogenesis is still unclear. Hypoxia-induced pulmonary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].